Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.
Mr. Becker brings more than 20 years of experience as a C-level industry executive and Wall Street securities analyst. Most recently, he was founder and president of the consulting firm MDB Communications LLC. In this position, he acted as a strategic advisor and partner servicing the life sciences industry by providing a full range of investor relations and public relations services to enhance client visibility and branding.
“We are very pleased to have Michael joining us as senior vice president of finance and corporate development,” said Sergio Traversa, CEO of Relmada. “He brings strong financial leadership and a wealth of industry experience to the company and is well-suited to lead our corporate development efforts during the continued evolution of Relmada. As a key member of our leadership team, Michael will be a tremendous asset as we approach planned clinical milestones and prepare to apply for uplisting on the NASDAQ Capital Market as soon as feasable.”
Mr. Becker previously served as president, chief executive officer, and member of the board of directors for publicly traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma). He held positions of increasing responsibility prior to being appointed president and CEO of Cytogen in 2002, including vice president of business development, industry and investor relations and CEO of AxCell Biosciences, a subsidiary of Cytogen. Prior to his industry career, Mr. Becker spent 9 years in the financial services industry, which includes positions at Wayne Hummer Investments LLC, Kidder, Peabody & Co., Gruntal & Co., and Kemper Securities. He completed coursework in Political Science at DePaul University and received an Associate of Science degree from the Art Institute of Pittsburgh.